JAMA Publishes GLORY-2 Trial of 9-mg Mazdutide for Weight Loss in Chinese Adults With Obesity

JAMA on June 7 published the GLORY-2 randomized clinical trial of 9-mg mazdutide in Chinese adults with obesity, adding peer-reviewed data to a drug program that Innovent Biologics says is headed toward a China filing.

The trial enrolled adults with obesity, with or without type 2 diabetes, across 27 hospitals in China. At 60 weeks, mean body weight change was -16.65% with mazdutide and -1.50% with placebo, according to the journal report.

The study also found a statistically significant higher rate of at least 5% weight loss with mazdutide than with placebo. Gastrointestinal adverse reactions were more common in the mazdutide group.

Innovent had previously said GLORY-2 met its primary and all key secondary endpoints and that it planned to submit a new drug application in China in the near term. The JAMA publication now places the data in the peer-reviewed record, but it does not resolve the timing of any regulatory decision.

What the publication adds

The new article provides the full randomized-trial report rather than only company topline results. That gives clinicians and investors a clearer view of the efficacy and safety profile for the 9-mg dose.

What remains open is straightforward: Chinese regulators have not announced a decision, and the eventual review timeline is still unknown.